Stock Research: Castle Biosciences

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Castle Biosciences

NasdaqGM:CSTL US14843C1053
23
  • Value
    100
  • Growth
    1
  • Safety
    Safety
    29
  • Combined
    25
  • Sentiment
    49
  • 360° View
    360° View
    23
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Castle Biosciences, Inc. is a diagnostics company improving health through tests that guide patient care. The company operates in the healthcare industry, focusing on diagnostic tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, with products including DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. No specific regions of operation are mentioned. In the last fiscal year, the company had a market cap of $549 million, profits of $272 million, revenue of $332 million, and 761 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 23 (better than 23% compared with alternatives), overall professional sentiment and financial characteristics for the stock Castle Biosciences are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Castle Biosciences. The only rank that is above average is the consolidated Safety Rank at 100, which means that the company has a financing structure that is safer than those of 100% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 29, which means that the share price of Castle Biosciences is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 1, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 49, which means that professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
29 7 35 26
Growth
1 24 11 55
Safety
Safety
100 79 73 84
Sentiment
49 65 69 47
360° View
360° View
23 25 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 97 93 97
Opinions Change
50 70 50 26
Pro Holdings
n/a 19 39 3
Market Pulse
58 40 47 72
Sentiment
49 65 69 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
29 7 35 26
Growth
1 24 11 55
Safety Safety
100 79 73 84
Combined
25 13 16 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
28 4 78 24
Price vs. Earnings (P/E)
16 7 12 3
Price vs. Book (P/B)
56 59 80 59
Dividend Yield
1 1 1 1
Value
29 7 35 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 4 27 74
Profit Growth
4 92 32 6
Capital Growth
7 6 18 95
Stock Returns
29 53 19 21
Growth
1 24 11 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
82 91 94 90
Refinancing
92 96 92 94
Liquidity
89 4 1 15
Safety Safety
100 79 73 84

Similar Stocks

Discover high‑ranked alternatives to Castle Biosciences and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.